Literature DB >> 23612585

Osteopontin: an emerging therapeutic target in uraemic vascular disease.

Xin Zhang, Alfonso Eirin, Amir Lerman, Lilach O Lerman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23612585      PMCID： PMC3656615          DOI： 10.1093/cvr/cvt098

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN： 0008-6363            Impact factor:   10.787


× No keyword cloud information.
  15 in total

1.  Neutralizing antibodies directed against osteopontin inhibit rat carotid neointimal thickening after endothelial denudation.

Authors:  L Liaw; D M Lombardi; M M Almeida; S M Schwartz; D deBlois; C M Giachelli
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-01       Impact factor: 8.311

2.  Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells.

Authors:  Susan K Nilsson; Hayley M Johnston; Genevieve A Whitty; Brenda Williams; Ryan J Webb; David T Denhardt; Ivan Bertoncello; Linda J Bendall; Paul J Simmons; David N Haylock
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

3.  Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.

Authors:  Neal X Chen; Kalisha D O'Neill; Danxia Duan; Sharon M Moe
Journal:  Kidney Int       Date:  2002-11       Impact factor: 10.612

4.  Smooth muscle cells deficient in osteopontin have enhanced susceptibility to calcification in vitro.

Authors:  Mei Y Speer; Yung-Ching Chien; Mary Quan; Hsueh-Ying Yang; Hojatollah Vali; Marc D McKee; Cecilia M Giachelli
Journal:  Cardiovasc Res       Date:  2005-05-01       Impact factor: 10.787

5.  Angiotensin II directly increases transforming growth factor beta1 and osteopontin and indirectly affects collagen mRNA expression in the human heart.

Authors:  C Kupfahl; D Pink; K Friedrich; H R Zurbrügg; M Neuss; C Warnecke; J Fielitz; K Graf; E Fleck; V Regitz-Zagrosek
Journal:  Cardiovasc Res       Date:  2000-06       Impact factor: 10.787

6.  Osteopontin deficiency attenuates atherosclerosis in female apolipoprotein E-deficient mice.

Authors:  Yutaka Matsui; Susan R Rittling; Hiroshi Okamoto; Manabu Inobe; Nan Jia; Toshihiro Shimizu; Masatoshi Akino; Takeshi Sugawara; Junko Morimoto; Chiemi Kimura; Shigeyuki Kon; David Denhardt; Akira Kitabatake; Toshimitsu Uede
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-05-01       Impact factor: 8.311

7.  Osteopontin transgenic mice fed a high-cholesterol diet develop early fatty-streak lesions.

Authors:  Kikuo Isoda; Yashuhiro Kamezawa; Makoto Ayaori; Masatoshi Kusuhara; Norihiro Tada; Fumitaka Ohsuzu
Journal:  Circulation       Date:  2003-02-11       Impact factor: 29.690

8.  Osteopontin is expressed in human aortic valvular lesions.

Authors:  K D O'Brien; J Kuusisto; D D Reichenbach; M Ferguson; C Giachelli; C E Alpers; C M Otto
Journal:  Circulation       Date:  1995-10-15       Impact factor: 29.690

9.  Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification.

Authors:  S Hirota; M Imakita; K Kohri; A Ito; E Morii; S Adachi; H M Kim; Y Kitamura; C Yutani; S Nomura
Journal:  Am J Pathol       Date:  1993-10       Impact factor: 4.307

10.  Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality.

Authors:  Gérard M London; Alain P Guérin; Sylvain J Marchais; Fabien Métivier; Bruno Pannier; Hasan Adda
Journal:  Nephrol Dial Transplant       Date:  2003-09       Impact factor: 5.992
View more
  2 in total

1.  Cardiac function in renovascular hypertensive patients with and without renal dysfunction.

Authors:  Kirandeep K Khangura; Alfonso Eirin; Garvan C Kane; Sanjay Misra; Stephen C Textor; Amir Lerman; Lilach O Lerman
Journal:  Am J Hypertens       Date:  2013-10-25       Impact factor: 2.689

2.  Inhibiting vascular smooth muscle cell proliferation mediated by osteopontin via regulating gut microbial lipopolysaccharide: A novel mechanism for paeonol in atherosclerosis treatment.

Authors:  Xiaoyan Shi; Hongfei Wu; Yarong Liu; Hanwen Huang; Ling Liu; Yulong Yang; Tingting Jiang; Min Zhou; Min Dai
Journal:  Front Pharmacol       Date:  2022-08-11       Impact factor: 5.988
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.